Mechanistically, the reduction of SHP expression in NASH was linked to inhibitory binding of c-Jun to the SHP promoter, suggesting that the JNK/SHP/NF-κB/CCL2 axis is a promising target for NASH prevention and treatment. The gene discussed is NR0B2; the disease is metabolic dysfunction-associated steatohepatitis.